Search

Your search keyword '"Fikre, Helina"' showing total 5 results
Start Over Author "Fikre, Helina" Publisher oxford university press (oup)
5 results on '"Fikre, Helina"'

1. Evaluation of Less Invasive Sampling Tools for the Diagnosis of Cutaneous Leishmaniasis

Author

van Henten, Saskia, primary, Kassa, Mekibib, additional, Fikre, Helina, additional, Melkamu, Roma, additional, Mekonnen, Tigist, additional, Dessie, Dilargachew, additional, Mulaw, Tadele, additional, Bogale, Tadfe, additional, Engidaw, Asinakew, additional, Yeshanew, Arega, additional, Cnops, Lieselotte, additional, Vogt, Florian, additional, Moons, Karel G M, additional, van Griensven, Johan, additional, and Pareyn, Myrthe, additional

Published
2024
Full Text
View/download PDF

2. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

Author

Musa, Ahmed M, primary, Mbui, Jane, additional, Mohammed, Rezika, additional, Olobo, Joseph, additional, Ritmeijer, Koert, additional, Alcoba, Gabriel, additional, Muthoni Ouattara, Gina, additional, Egondi, Thaddaeus, additional, Nakanwagi, Prossy, additional, Omollo, Truphosa, additional, Wasunna, Monique, additional, Verrest, Luka, additional, Dorlo, Thomas P C, additional, Musa Younis, Brima, additional, Nour, Ali, additional, Taha Ahmed Elmukashfi, Elmukashfi, additional, Ismail Omer Haroun, Ahmed, additional, Khalil, Eltahir A G, additional, Njenga, Simon, additional, Fikre, Helina, additional, Mekonnen, Tigist, additional, Mersha, Dagnew, additional, Sisay, Kasaye, additional, Sagaki, Patrick, additional, Alvar, Jorge, additional, Solomos, Alexandra, additional, and Alves, Fabiana, additional

Published
2022
Full Text
View/download PDF

3. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa : A Randomized, Controlled, Multicountry Trial.

Author

Musa, Ahmed M, Mbui, Jane, Mohammed, Rezika, Olobo, Joseph, Ritmeijer, Koert, Alcoba, Gabriel, Muthoni Ouattara, Gina, Egondi, Thaddaeus, Nakanwagi, Prossy, Omollo, Truphosa, Wasunna, Monique, Verrest, Luka, Dorlo, Thomas P. C., Musa Younis, Brima, Nour, Ali, Taha Ahmed Elmukashfi, Elmukashfi, Ismail Omer Haroun, Ahmed, Khalil, Eltahir A G, Njenga, Simon, Fikre, Helina, Mekonnen, Tigist, Mersha, Dagnew, Sisay, Kasaye, Sagaki, Patrick, Alvar, Jorge, Solomos, Alexandra, Alves, Fabiana, Musa, Ahmed M, Mbui, Jane, Mohammed, Rezika, Olobo, Joseph, Ritmeijer, Koert, Alcoba, Gabriel, Muthoni Ouattara, Gina, Egondi, Thaddaeus, Nakanwagi, Prossy, Omollo, Truphosa, Wasunna, Monique, Verrest, Luka, Dorlo, Thomas P. C., Musa Younis, Brima, Nour, Ali, Taha Ahmed Elmukashfi, Elmukashfi, Ismail Omer Haroun, Ahmed, Khalil, Eltahir A G, Njenga, Simon, Fikre, Helina, Mekonnen, Tigist, Mersha, Dagnew, Sisay, Kasaye, Sagaki, Patrick, Alvar, Jorge, Solomos, Alexandra, and Alves, Fabiana

Abstract

BACKGROUND: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa. METHODS: An open-label, phase 3, randomized, controlled trial was conducted in adult and pediatric patients at 7 sites in eastern Africa. Patients were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days). The primary endpoint was definitive cure after 6 months. RESULTS: Of 439 randomized patients, 424 completed the trial. Definitive cure at 6 months was 91.2% (155 of 170) and 91.8% (156 of 170) in the PM/MF and SSG/PM arms in primary efficacy modified intention-to-treat analysis (difference, 0.6%; 97.5% confidence interval [CI], -6.2 to 7.4), narrowly missing the noninferiority margin of 7%. In the per-protocol analysis, efficacy was 92% (149 of 162) and 91.7% (155 of 169) in the PM/MF and SSG/PM arms (difference, -0.3%; 97.5% CI, -7.0 to 6.5), demonstrating noninferiority. Treatments were well tolerated. Four of 18 serious adverse events were study drug-related, and 1 death was SSG-related. Allometric dosing ensured similar MF exposure in children (<12 years) and adults. CONCLUSIONS: PM/MF and SSG/PM efficacies were similar, and adverse drug reactions were as expected given the drugs safety profiles. With 1 less injection each day, reduced treatment duration, and no risk of SSG-associated life-threatening cardiotoxicity, PM/MF is a more patient-friendly alternative for children and adults with primary visceral leishmaniasis in eastern Africa. Clinical Trials Registration. NCT03129646.

Published
2022
Full Text
View/download PDF

5. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus–Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial

Author

Diro, Ermias, primary, Ritmeijer, Koert, additional, Boelaert, Marleen, additional, Alves, Fabiana, additional, Mohammed, Rezika, additional, Abongomera, Charles, additional, Ravinetto, Raffaella, additional, De Crop, Maaike, additional, Fikre, Helina, additional, Adera, Cherinet, additional, van Loen, Harry, additional, Tsoumanis, Achilleas, additional, Adriaensen, Wim, additional, Hailu, Asrat, additional, and Griensven, Johan van, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results